Safety considerations for the management of cholestatic itch

References

• Ikoma A, Rukwied R, Stander S, et al. Neurophysiology of pruritus: interaction of itch and pain. Arch Dermatol. 2003 Nov;139(11):1475–1478.
   PubMedGoogle Scholar
• Williamson C, Geenes V. Intrahepatic cholestasis of pregnancy. Obstet Gynecol. 2014 Jul;124(1):120–133.
   PubMed Web of Science ®Google Scholar
• Baker A, Kerkar N, Todorova L, et al. Systematic review of progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol. 2019 Feb;43(1):20–36.
   PubMed Web of Science ®Google Scholar
• Talwalkar JA, Souto E, Jorgensen RA, et al. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2003 Jul;1(4):297–302.
   PubMed Web of Science ®Google Scholar
• Hegade VS, Mells GF, Fisher H, et al. Pruritus is common and undertreated in patients with primary biliary cholangitis in the United Kingdom. Clin Gastroenterol Hepatol. 2019 Jun;17(7):1379–1387 e3.
   PubMed Web of Science ®Google Scholar
• Al-Ali J, Al-Mutari N, Ahmed ESF. Hepatitis C virus and the skin. Hepatogastroenterology. 2011 May-Jun;58(107–108):880–886.
   PubMedGoogle Scholar
• Oeda S, Takahashi H, Yoshida H, et al. Prevalence of pruritus in patients with chronic liver disease: a multicenter study. Hepatol Res. 2018 Feb;48(3):E252–E262.
   PubMed Web of Science ®Google Scholar
• Fujino H, Tanaka M, Imamura M, et al. Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis. BMC Gastroenterol. 2019 Oct 24;19(1):169.
   PubMed Web of Science ®Google Scholar
• Beuers U, Kremer AE, Bolier R, et al. Pruritus in cholestasis: facts and fiction. Hepatology. 2014 Jul;60(1):399–407.
   PubMed Web of Science ®Google Scholar
• Dhand A, Aminoff MJ. The neurology of itch. Brain. 2014 Feb;137(Pt 2):313–322.
   PubMedGoogle Scholar
• Dull MM, Kremer AE. Treatment of pruritus secondary to liver disease. Curr Gastroenterol Rep. 2019 Jul 31;21(9):48.
   PubMedGoogle Scholar
• Carrion AF, Rosen JD, Understanding LC. Treating pruritus in primary biliary cholangitis. Clin Liver Dis. 2018 Aug;22(3):517–532.
   PubMed Web of Science ®Google Scholar
• Kremer AE, Martens JJ, Kulik W, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology. 2010 Sep;139(3):1008–1018.
   PubMed Web of Science ®Google Scholar
• Kremer AE, Van Dijk R, Leckie P, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology. 2012 Oct;56(4):1391–1400.
   PubMed Web of Science ®Google Scholar
• Datta DV, Sherlock S. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology. 1966 Mar;50(3):323–332.
   PubMed Web of Science ®Google Scholar
• Di Padova C, Tritapepe R, Rovagnati P, et al. Double-blind placebo-controlled clinical trial of microporous cholestyramine in the treatment of intra- and extra-hepatic cholestasis: relationship between itching and serum bile acids. Methods Find Exp Clin Pharmacol. 1984 Dec;6(12):773–776.
   PubMedGoogle Scholar
• Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the study of liver diseases. Hepatology. 2019 Jan;69(1):394–419.
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Beuers U, Corpechot C, European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017 Jul;67(1):145–172.
   PubMed Web of Science ®Google Scholar
• Scaldaferri F, Pizzoferrato M, Ponziani FR, et al. Use and indications of cholestyramine and bile acid sequestrants. Intern Emerg Med. 2013 Apr;8(3):205–210.
   PubMed Web of Science ®Google Scholar
• Rust C, Sauter GH, Oswald M, et al. Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man. Eur J Clin Invest. 2000 Feb;30(2):135–139.
   PubMed Web of Science ®Google Scholar
• Kuiper EM, Van Erpecum KJ, Beuers U, et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology. 2010 Oct;52(4):1334–1340.
   PubMed Web of Science ®Google Scholar
• Graffner H, Gillberg PG, Rikner L, et al. The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation. Aliment Pharmacol Ther. 2016 Jan;43(2):303–310.
   PubMed Web of Science ®Google Scholar
• Hegade VS, Kendrick SF, Dobbins RL, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet. 2017 Mar 18;389(10074):1114–1123.
   PubMed Web of Science ®Google Scholar
• Levy C, Kendrick S, Bowlus C, et al. GLIMMER TRIAL - a randomized double-blind, placebo-controlled study of linerixibat, an inhibitor of the ileal bile acid transporter, in the treatment of cholestatic pruritus in primary biliary cholangitis. Hepatology. 2020;72(S1):131A–1159A.
   Google Scholar
• Mayo MJ, Pockros PJ, Jones D, et al. A randomized, controlled, phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis. Hepatol Commun. 2019 3; Mar(3): 365–381.
   Google Scholar
• Tandon P, Rowe BH, Vandermeer B, et al. The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol. 2007 Jul;102(7):1528–1536.
   PubMed Web of Science ®Google Scholar
• Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized- controlled trials. Liver Int. 2006 Oct;26(8):943–948.
   PubMed Web of Science ®Google Scholar
• Bolier R, Oude Elferink RP, Beuers U. Advances in pathogenesis and treatment of pruritus. Clin Liver Dis. 2013 May;17(2):319–329.
   PubMed Web of Science ®Google Scholar
• Podesta A, Lopez P, Terg R, et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci. 1991 Feb;36(2):216–220.
   PubMed Web of Science ®Google Scholar
• Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology. 1988 Feb;94(2):488–493.
   PubMed Web of Science ®Google Scholar
• Bachs L, Pares A, Elena M, et al. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology. 1992 Jun;102(6):2077–2080.
   PubMed Web of Science ®Google Scholar
• Yerushalmi B, Sokol RJ, Narkewicz MR, et al. Use of rifampin for severe pruritus in children with chronic cholestasis. J Pediatr Gastroenterol Nutr. 1999 Oct;29(4):442–447.
   PubMed Web of Science ®Google Scholar
• Webb GJ, Rahman SR, Levy C, et al. Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study. Aliment Pharmacol Ther. 2018 Apr;47(8):1213–1219.
   PubMed Web of Science ®Google Scholar
• Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut. 2002 Mar;50(3):436–439.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee, clinical practice guideline panel c, panel m, et al. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol. 2019 Jun;70(6):1222–1261.
   PubMed Web of Science ®Google Scholar
• Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis. 1983 Jul-Aug;5(Suppl 3):S440–50.
   PubMedGoogle Scholar
• Martinez E, Collazos J, Mayo J. Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine (Baltimore). 1999 Nov;78(6):361–369.
   PubMed Web of Science ®Google Scholar
• Alfarisi O, Alghamdi WA, Al-Shaer MH, et al. Rifampin vsrifapentine: what is the preferred rifamycin for tuberculosis? Expert Rev Clin Pharmacol. 2017 Oct;10(10):1027–1036.
   PubMed Web of Science ®Google Scholar
• Ghonem NS, Assis DN, Boyer JL. Fibrates and cholestasis. Hepatology. 2015 Aug;62(2):635–643.
   PubMed Web of Science ®Google Scholar
• Honda A, Tanaka A, Kaneko T, et al. Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis. Hepatology. 2019 Dec;70(6):2035–2046.
   PubMed Web of Science ®Google Scholar
• De Vries E, Bolier R, Goet J, et al. Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double blind, randomized, placebo-controlled trial. Gastroenterology. 2020 Oct 5;160(3):734–743.e6.
   PubMed Web of Science ®Google Scholar
• Kanda T, Yokosuka O, Imazeki F, et al. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol. 2003;38(6):573–578.
   PubMed Web of Science ®Google Scholar
• Iwasaki S, Ohira H, Nishiguchi S, et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study. Hepatol Res. 2008 Jun;38(6):557–564.
   PubMed Web of Science ®Google Scholar
• Corpechot C, Chazouilleres O, Rousseau A, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med. 2018 Jun 7;378(23):2171–2181.
   PubMed Web of Science ®Google Scholar
• Grigorian AY, Mardini HE, Corpechot C, et al. Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: a meta-analysis. Clin Res Hepatol Gastroenterol. 2015 Jun;39(3):296–306.
   PubMed Web of Science ®Google Scholar
• Blane GF. Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. Am J Med. 1987 Nov 27;83(5):(5B):26–36.
   PubMedGoogle Scholar
• Amend KL, Landon J, Thyagarajan V, et al. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population. Ann Pharmacother. 2011 Oct;45(10):1230–1239.
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 Nov 26;366(9500):1849–1861.
   PubMed Web of Science ®Google Scholar
• Zhao S, Wang F, Dai Y, et al. Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment. Int J Cardiol. 2016 Oct;15(221):832–836.
   Google Scholar
• Hottelart C, El Esper N, Rose F, et al. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 2002;92(3):536–541.
   PubMed Web of Science ®Google Scholar
• Pdds J, Parés A, Kowdley KV, et al. LBO-02-Elafibranor, a peroxisome proliferator-activted receptor alpha and delta agonist demonstrates favourable efficacy and safety in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid treatment. J Hepatol. 2019;70(1):e128.
   Web of Science ®Google Scholar
• Levy C, Bowlus C, Neff G, et al. FRI133 - Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study. J Hepatol. 2020;73:S464–S465.
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Yosipovitch G. Itching as a systemic disease. J Allergy Clin Immunol. 2019 Aug;144(2):375–380.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Rosen JD, Hashimoto T. Itch: from mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. 2018 Nov;142(5):1375–1390.
   PubMed Web of Science ®Google Scholar
• Wolfhagen FH, Sternieri E, Hop WC, et al. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology. 1997;113(4):1264–1269.
   PubMed Web of Science ®Google Scholar
• Terg R, Coronel E, Sorda J, et al. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol. 2002 Dec;37(6):717–722.
   PubMed Web of Science ®Google Scholar
• Bergasa NV. Effects of naloxone infusions in patients with the pruritus of cholestasis: a double-blind, randomized, controlled trial. Ann Intern Med. 1995;123(3):161–167.
   PubMed Web of Science ®Google Scholar
• Jones EA, Dekker LRC. Florid opioid withdrawal–like reaction precipitated by naltrexone in a patient with chronic cholestasis.Gastroenterology. 2000;118(2):431–432.
   PubMed Web of Science ®Google Scholar
• McRae CA, Prince MI, Hudson M, et al. Pain as a complication of use of opiate antagonists for symptom control in cholestasis. Gastroenterology. 2003;125(2):591–596.
   PubMed Web of Science ®Google Scholar
• Kamimura K, Yokoo T, Kamimura H, et al. Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: patient-reported outcome based analyses. PLoS One. 2017;12(6):e0178991.
   PubMed Web of Science ®Google Scholar
• Kumada H, Miyakawa H, Muramatsu T, et al. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial. Hepatol Res. 2017 Sep;47(10):972–982.
   PubMed Web of Science ®Google Scholar
• Lipman ZM, Yosipovitch G. An evaluation of difelikefalin as a treatment option for moderate-to-severe pruritus in end stage renal disease. Expert Opin Pharmacother. 2021 Apr;22(5):549–555.
   Google Scholar
• Albert-Vartanian A, Boyd MR, Hall AL, et al. Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? J Clin Pharm Ther. 2016 Aug;41(4):371–382.
   PubMed Web of Science ®Google Scholar
• Fishbane S, Jamal A, Munera C, et al. A phase 3 trial of difelikefalin in hemodialysis patients with pruritus. N Engl J Med. 2020 Jan 16;382(3):222–232.
   PubMed Web of Science ®Google Scholar
• Golpanian RS, Yosipovitch G, Levy C. Use of butorphanol as treatment for cholestatic itch. Dig Dis Sci. 2020 Jun;18.
   Google Scholar
• Mayo MJ, Handem I, Saldana S, et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007 Mar;45(3):666–674.
   PubMed Web of Science ®Google Scholar
• Shelton RC. The nature of the discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry. 2006;67(Suppl 4):3–7.
   PubMed Web of Science ®Google Scholar
• Wang RZ, Vashistha V, Kaur S, et al. Serotonin syndrome: preventing, recognizing, and treating it. Cleve Clin J Med. 2016 Nov;83(11):810–817.
   PubMed Web of Science ®Google Scholar
• Jones EA, Molenaar HA, Oosting J. Ondansetron and pruritus in chronic liver disease: a controlled study. Hepatogastroenterology. 2007 Jun;54(76):1196–1199.
   PubMedGoogle Scholar
• Muller C, Pongratz S, Pidlich J, et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol. 1998 Oct;10(10):865–870.
   PubMed Web of Science ®Google Scholar
• Gunal AI, Ozalp G, Yoldas TK, et al. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant. 2004 Dec;19(12):3137–3139.
   PubMed Web of Science ®Google Scholar
• Razeghi E, Eskandari D, Ganji MR, et al. Gabapentin and uremic pruritus in hemodialysis patients. Ren Fail. 2009;31(2):85–90.
   PubMed Web of Science ®Google Scholar
• Li Z, Taylor CP, Weber M, et al. Pregabalin is a potent and selective ligand for alpha(2)delta-1 and alpha(2)delta-2 calcium channel subunits. Eur J Pharmacol. 2011 Sep 30;667(1–3):80–90.
   PubMed Web of Science ®Google Scholar
• Quintero JE, Dooley DJ, Pomerleau F, et al. Amperometric measurement of glutamate release modulation by gabapentin and pregabalin in rat neocortical slices: role of voltage-sensitive Ca2+ alpha2delta-1 subunit. J Pharmacol Exp Ther. 2011 Jul;338(1):240–245.
   PubMed Web of Science ®Google Scholar
• Bergasa NV, McGee M, Ginsburg IH, et al. Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2006 Nov;44(5):1317–1323.
   PubMed Web of Science ®Google Scholar
• Azimi E, Reddy VB, Pereira PJS, et al. Substance P activates Mas-related G protein-coupled receptors to induce itch. J Allergy Clin Immunol. 2017 Aug;140(2):447–453 e3.
   PubMed Web of Science ®Google Scholar
• Trivedi M, Bergasa NV. Serum concentrations of substance P in cholestasis. Ann Hepatol. 2010 Apr-Jun;9(2):177–180.
   PubMed Web of Science ®Google Scholar
• Li WW, Guo TZ, Liang DY, et al. Substance P signaling controls mast cell activation, degranulation, and nociceptive sensitization in a rat fracture model of complex regional pain syndrome. Anesthesiology. 2012 Apr;116(4):882–895.
   PubMed Web of Science ®Google Scholar
• Stander S, Siepmann D, Herrgott I, et al. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010 Jun 4;5(6):e10968.
   PubMed Web of Science ®Google Scholar
• Dando TM, Perry CM. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs. 2004;64(7):777–794.
   PubMed Web of Science ®Google Scholar
• Gingold AR, Bergasa NV. The cannabinoid agonist WIN 55, 212-2 increases nociception threshold in cholestatic rats: implications for the treatment of the pruritus of cholestasis. Life Sci. 2003 Oct 10;73(21):2741–2747.
   PubMed Web of Science ®Google Scholar
• Dvorak M, Watkinson A, McGlone F, et al. Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm Res. 2003 Jun;52(6):238–245.
   PubMed Web of Science ®Google Scholar
• Neff GW, O’Brien CB, Reddy KR, et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol. 2002 Aug;97(8):2117–2119.
   PubMed Web of Science ®Google Scholar
• Legat FJ. The antipruritic effect of phototherapy. Front Med (Lausanne). 2018;5:333.
   PubMed Web of Science ®Google Scholar
• Decock S, Roelandts R, Steenbergen WV, et al. Cholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study. J Hepatol. 2012 Sep;57(3):637–641.
   PubMed Web of Science ®Google Scholar
• Hanid MA, Levi AJ. Phototherapy for pruritus in primary biliary cirrhosis. Lancet. 1980 Sep 6;2(8193):530.
   PubMed Web of Science ®Google Scholar
• Pinheiro NC, Marinho RT, Ramalho F, et al. Refractory pruritus in primary biliary cirrhosis. BMJ Case Rep. 2013Nov;14.
   Google Scholar
• Cerio R, Murphy GM, Sladen GE, et al. A combination of phototherapy and cholestyramine for the relief of pruritus in primary biliary cirrhosis. Br J Dermatol. 1987 Feb;116(2):265–267.
   PubMed Web of Science ®Google Scholar
• Krawczyk M, Liebe R, Wasilewicz M, et al. Plasmapheresis exerts a long-lasting antipruritic effect in severe cholestatic itch. Liver Int. 2017 May;37(5):743–747.
   PubMed Web of Science ®Google Scholar
• Pares A, Herrera M, Aviles J, et al. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol. 2010 Aug;53(2):307–312.
   PubMed Web of Science ®Google Scholar
• Hegade VS, Krawczyk M, Kremer AE, et al. The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study. Aliment Pharmacol Ther. 2016 Jan;43(2):294–302.
   PubMed Web of Science ®Google Scholar